Free Trial
→ Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (From Colonial Metals) (Ad) Free BLUE Stock Alerts

bluebird bio (BLUE) Stock Forecast & Price Target

bluebird bio logo
$0.30 0.00 (0.00%)
(As of 11/20/2024 ET)
Compare

bluebird bio - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold
Based on 11 Analyst Ratings
Sell
2
Hold
7
Buy
2

Based on 11 Wall Street analysts who have issued ratings for bluebird bio in the last 12 months, the stock has a consensus rating of "Hold." Out of the 11 analysts, 2 have given a sell rating, 7 have given a hold rating, and 2 have given a buy rating for BLUE.

Consensus Price Target

$3.03
898.35% Upside
According to the 11 analysts' twelve-month price targets for bluebird bio, the average price target is $3.03. The highest price target for BLUE is $7.00, while the lowest price target for BLUE is $0.50. The average price target represents a forecasted upside of 898.35% from the current price of $0.30.
Get the Latest News and Ratings for BLUE and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for bluebird bio and its competitors.

Sign Up

BLUE Analyst Ratings Over Time

TypeCurrent Forecast
11/22/23 to 11/21/24		1 Month Ago
10/23/23 to 10/22/24		3 Months Ago
8/24/23 to 8/23/24		1 Year Ago
11/22/22 to 11/22/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
6 Buy rating(s)
Hold
7 Hold rating(s)
7 Hold rating(s)
7 Hold rating(s)
5 Hold rating(s)
Sell
2 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$3.03$4.63$4.74$7.62
Forecasted Upside898.35% Upside816.22% Upside588.90% Upside101.08% Upside
Consensus Rating
Hold
Hold
Hold
Hold

BLUE Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BLUE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

bluebird bio Stock vs. The Competition

Typebluebird bioMedical CompaniesS&P 500
Consensus Rating Score
2.00
2.80
2.50
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside898.35% Upside26,931.55% Upside9.81% Upside
News Sentiment Rating
Neutral News

See Recent BLUE News
Neutral News
Positive News
Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/15/2024Royal Bank of Canada
4 of 5 stars		 Reiterated RatingSector Perform ➝ Sector Perform$4.00 ➝ $4.00+1,142.59%
11/15/2024Barclays
3 of 5 stars		 Lower TargetOverweight ➝ Overweight$4.00 ➝ $2.00+502.58%
11/15/2024JPMorgan Chase & Co.
3 of 5 stars		 DowngradeNeutral ➝ Underweight
11/15/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeBuy ➝ Neutral$3.00 ➝ $0.50+37.89%
9/25/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetEqual Weight ➝ Equal Weight$3.00 ➝ $2.00+315.36%
9/16/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingNeutral
8/15/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOutperform ➝ Outperform$7.00 ➝ $6.00+636.28%
3/19/2024Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetNeutral ➝ Neutral$1.72 ➝ $1.68+16.67%
3/5/2024HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetReduce ➝ Reduce$2.31 ➝ $1.02-33.33%
1/9/2024William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingMarket Perform
12/8/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeUnderweight ➝ Equal Weight$3.00 ➝ $7.00+45.53%
11/8/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOutperform ➝ Outperform$10.00 ➝ $13.00+267.23%
1/23/2023Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetMarket Perform$9.00 ➝ $8.00+29.24%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 09:03 AM ET.


BLUE Forecast - Frequently Asked Questions

According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for bluebird bio is $3.03, with a high forecast of $7.00 and a low forecast of $0.50.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last year. There are currently 2 sell ratings, 7 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BLUE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLUE, but not buy additional shares or sell existing shares.

According to analysts, bluebird bio's stock has a predicted upside of 898.35% based on their 12-month stock forecasts.

Over the previous 90 days, bluebird bio's stock had 2 downgrades by analysts.

bluebird bio has been rated by research analysts at Bank of America, Barclays, Cantor Fitzgerald, JPMorgan Chase & Co., Royal Bank of Canada, and Wells Fargo & Company in the past 90 days.

Analysts like bluebird bio less than other "medical" companies. The consensus rating for bluebird bio is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how BLUE compares to other companies.

Related Companies
Today's Ratings
Top Rated Stocks
More Ratings Tools

This page (NASDAQ:BLUE) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners
Unveiled: NVIDIA’s "Secret Royalty" Program
Did you know that there's an investment that will give you the opportunity to collect "royalties" every time N...
Behind the Markets | Sponsored